Jump to content

OmniVis: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
added photo
added external link
Line 31: Line 31:
<!-- Inline citations added to your article will automatically display here. See en.wikipedia.org/wiki/WP:REFB for instructions on how to add citations. -->
<!-- Inline citations added to your article will automatically display here. See en.wikipedia.org/wiki/WP:REFB for instructions on how to add citations. -->
{{reflist}}
{{reflist}}

== External link ==

* [https://www.omnivistech.com/ Official website]

Revision as of 15:38, 31 December 2021

  • Comment: Remove all non-notable awards to start with. Nomadicghumakkad (talk) 20:44, 1 November 2021 (UTC)
OmniVis
IndustryBiotechnology
Founded2017
HeadquartersSan Francisco, California, USA
Key people
Katherine Clayton, CEO
Websitewww.omnivistech.com

Dr Katherine Clayton of OmniVis at TechCrunch Disrupt San Francisco 2019

OmniVis is a US biotechnology company that specialises in rapid medical diagnostic tests.[1][2][3]

OmiVis's OmniTech rapid Cholera detection device can identify the presence of Vibrio cholerae in water in less than one hour (35 minutes average on one study and 47 minutes in another), notably faster than previous technologies that take three days.[4][5] OmniTech uses a process of DNA amplification and viscosity measurement and costs approximately US$10 per test.[6]

The processing is done on an Android smartphone[6] that analyses water samples that are put into a single-use test kit element.[1]

The current design is not well suited for large scale testing due to the small volume that can be tested.[1]

In May 2020, OmniVis was working on the early stages of a rapid test for COVID-19[7] that detects the disease in human saliva. The rapid tests uses a smartphone for processing.[7] The project was supported by the United Stated Department of Agriculture.[8] From June 2020, Omnivis was also working on a United States National Science Foundation funded initiative to detect COVID-19 from nasal swabs.[9]

References

  1. ^ a b c Joe Palca and Susie Neilson (7 Aug 2019). "This Handy New Device Might Help KO Cholera". NPR.org. Retrieved 2021-10-31.
  2. ^ "Purdue Spinout OmniVis Commercializing Smartphone-Based Cholera Test". Genomeweb. 2019-02-15. Retrieved 2021-11-02.
  3. ^ Prashantham, Shameen. Gorillas Can Dance: Lessons from Microsoft and Other Corporations on Partnering with Startups. United Kingdom: Wiley, 2021. p.p. lviii
  4. ^ Rager, Theresa L.; Koepfli, Cristian; Khan, Wasif A.; Ahmed, Sabeena; Mahmud, Zahid Hayat; Clayton, Katherine N. (2021-05-12). "Usability of Rapid Cholera Detection Device (OmniVis) for Water Quality Workers in Bangladesh: Iterative Convergent Mixed Methods Study". Journal of Medical Internet Research. 23 (5): e22973. doi:10.2196/22973.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  5. ^ Moehling, Taylor J; Lee, Dong Hoon; Henderson, Meghan E; McDonald, Mariah K; Tsang, Preston H; Kaakeh, Seba; Kim, Eugene S; Wereley, Steven T; Kinzer-Ursem, Tamara L; Clayton, Katherine N; Linnes, Jacqueline C (2020-11-01). "A smartphone-based particle diffusometry platform for sub-attomolar detection of Vibrio cholerae in environmental water". Biosensors & bioelectronics. 167: 112497. doi:10.1016/j.bios.2020.112497. ISSN 1873-4235. PMC 7532658. PMID 32836088.
  6. ^ a b Coldewey, Devin (2 Oct 2019). "OmniVis could save lives by detecting cholera-infected water in minutes rather than days". TechCrunch. Retrieved 2021-10-31.{{cite web}}: CS1 maint: url-status (link)
  7. ^ a b Marcus, Brianna Abbott and Amy Dockser (2020-05-26). "Race Is On to Create Rapid Covid-19 Tests for the Fall". Wall Street Journal. ISSN 0099-9660. Retrieved 2021-10-31.
  8. ^ "COVID-19 Rapid Response: A Handheld Diagnostic Device for COVID-19 in Meat and Poultry Processing Facilities - OMNIVIS INC". portal.nifa.usda.gov. Retrieved 2021-12-17.
  9. ^ "NSF Award Search: Award # 2028308 - SBIR Phase I: COVID-19 Detection on a Handheld Smartphone-Enabled Platform". www.nsf.gov. Retrieved 2021-12-17.